SEC 13F Intelligence

Managers / Q4 2025 · view latest →

SECTORAL ASSET MANAGEMENT INC

CIK 0001274413 · 1010 SHERBROOKE ST., WEST, SUITE 1610, MONTREAL, A8, H3A 2R7 · 514 849 8777

Reported Value
$125M
Q4 2025
Positions
74
Filings on Record
30
2019–present window
Filed
Feb 9, 2026
original filing

Summary

Sectoral Asset Management Inc reported $125M in U.S.-listed holdings across 74 positions for Q4 2025.

Its largest position, EVMN, represents 8.1% of the portfolio.

Compared with Q3 2025, the fund opened 6 new positions and exited 14.

Portfolio Metrics

Turnover
+19.3%
vs prior filed quarter
Top-10 Concentration
+46.1%
share of reported value
Largest Position
+8.1%
Evommune
New / Exited
6 / 14
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $736MQ4 ’18Q1 ’19: $831MQ2 ’19: $836MQ3 ’19: $580MQ4 ’19: $670MQ4 ’19Q1 ’20: $521MQ2 ’20: $1.1BQ3 ’20: $1.2BQ4 ’20: $1.4BQ4 ’20Q1 ’21: $1.3BQ2 ’21: $1.2BQ3 ’21: $1.2BQ4 ’21: $664MQ4 ’21Q1 ’22: $563MQ2 ’22: $496MQ3 ’22: $508MQ4 ’22: $517MQ4 ’22Q1 ’23: $520MQ2 ’23: $600MQ3 ’23: $514MQ4 ’23: $232MQ4 ’23Q1 ’24: $254MQ2 ’24: $246MQ3 ’24: $169MQ4 ’24: $150MQ4 ’24Q1 ’25: $128MQ2 ’25: $151MQ3 ’25: $162MQ4 ’25: $125MQ4 ’25Q1 ’26: $121Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 90.6%ADR: 6.4%Other: 3.0%
  • Common Stock · 90.6% · $113M
  • ADR · 6.4% · $8M
  • Other · 3.0% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
EVMNEVOMMUNE INCNEW+589.0K589.0K+$10M$10M
COGTCOGENT BIOSCIENCES INCNEW+32.7K32.7K+$1M$1M
LENZLENZ THERAPEUTICS INCNEW+42.5K42.5K+$680,000$680,000
INSPINSPIRE MED SYS INCNEW+7.2K7.2K+$664,056$664,056
CARLCARLSMED INCNEW+47.7K47.7K+$589,095$589,095
NKTRNEKTAR THERAPEUTICSNEW+13.5K13.5K+$570,146$570,146
UTHUNITED THERAPEUTICSADDED+9581.7K+$518,836$839,532
ANABANAPTYSBIO INCSOLD OUT−194.5K0−$6M$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2025

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1EVMNEVOMMUNE INChistory →COM SHS8.08%$10M589.0K
2CTNMCONTINEUM THERAPEUTICShistory →CL A7.34%$9M800.8K
3LLYELI LILLY & COhistory →COM6.27%$8M7.3K
4SISHOULDER INNOVATIONShistory →COMMON STOCK5.64%$7M492.4K
5UNHUNITEDHEALTH GRP INChistory →COM3.60%$4M13.6K
6AMGNAMGEN INChistory →COM3.43%$4M13.1K
7JNJJOHNSON & JOHNSONhistory →COM3.37%$4M20.3K
8ABBVABBVIE INChistory →COM3.08%$4M16.8K
9VRTXVERTEX PHARMAhistory →COM2.91%$4M8.0K
10ABTABBOTT LABShistory →COM2.36%$3M23.5K
11REGNREGENERON PHARMCTCLShistory →COM2.30%$3M3.7K
12ISRGINTUITIVE SURGIC INChistory →COM NEW2.20%$3M4.8K
13BSXBOSTON SCIENTIFIChistory →COM2.11%$3M27.6K
14ARGXARGENX SE SPN ADRhistory →SP ADR1.95%$2M2.9K
15DHRDANAHER CORPhistory →COM1.94%$2M10.6K
16SYKSTRYKER CORPhistory →COM1.85%$2M6.5K
17TMOTHERMO FISHER SCIENTIFIChistory →COM1.81%$2M3.9K
18MRKMERCK & CO INChistory →COM1.81%$2M21.4K
19GILDGILEAD SCIENCES INChistory →COM1.76%$2M17.9K
20IM8NINSMED INChistory →COM PAR $.011.56%$2M11.2K
21DC4DEXCOM INChistory →COM1.53%$2M28.7K
22VERAVERA THERAPEUTICShistory →CL A1.50%$2M36.9K
23GPCRSTRUCTURE THERAPEUTICShistory →SP ADR1.33%$2M23.9K
24BNTXBIONTECH SEhistory →SP ADR1.31%$2M17.2K
25EWEDWARDS LIFESCIENCEhistory →COM1.18%$1M17.3K
26AZNNASTRAZENECAhistory →SP ADR1.12%$1M15.2K
27SMMTSUMMIT THERAPEUTICShistory →COM1.12%$1M79.6K
28RCUSARCUS BIOSCIENCEShistory →COM1.09%$1M56.9K
29SNDXSYNDAX PHARMACEUTICALShistory →COM1.03%$1M61.2K
30TARSTARSUS PHARMACEUTICALCOM0.97%$1M14.7K
31ALNYALNYLAM PHARMACEUTICALS INCCOM0.95%$1M3.0K
32RAPPRAPPORT THERAPEUTICSCOM0.95%$1M38.9K
33COGTCOGENT BIOSCIENCES INCCOM0.93%$1M32.7K
34MLYSMINERALYS THERAPEUTICSCOM0.92%$1M31.6K
35TRVITREVI THERAPEUTIC INCCOM0.85%$1M84.3K
36ROIVANT SCIENCES LTDSHS0.79%$984,03045.3K
37TECXTECTONIC THERAPEUTICSCOM0.71%$881,43942.3K
38VTYXUSDVENTYX BIOSCIENCESCOM0.70%$875,41396.9K
39BBIOBRIDGEBIO PHARMACOM0.68%$854,39311.2K
40UTHUNITED THERAPEUTICSCOM0.67%$839,5321.7K
41BOLDBOUNDLESS BIO INCCOM0.65%$814,289678.6K
42ONCBEONE MEDICINES LTDSP ADR0.65%$809,6542.7K
43RDNTRADNET INCCOM0.63%$784,85011.0K
44AVBPARRIVENT BIOPHARMACOM0.62%$769,69138.3K
45UNIQURE N.V.SHS0.59%$731,89930.6K
46ASCENDIS PHARMASP ADR0.56%$693,8833.3K
47LENZLENZ THERAPEUTICS INCCOM0.55%$680,00042.5K
48PFEPFIZER INCCOM0.54%$676,03527.1K
49INSPINSPIRE MED SYS INCCOM0.53%$664,0567.2K
50ISIIONIS PHARMACEUTICALCOM0.53%$661,7558.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$121M77May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$125M74Feb 9, 202613F-HRchanges · EDGAR ↗
Q3 2025$162M82Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$151M94Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$128M84May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$150M86Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$169M90Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$246M97Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$254M92May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$232M104Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$514M123Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$600M121Aug 11, 202313F-HRchanges · EDGAR ↗
Q1 2023$520M118May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022$517M120Feb 10, 202313F-HRchanges · EDGAR ↗
Q3 2022$508M109Nov 10, 202213F-HRchanges · EDGAR ↗
Q2 2022$496M112Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$563M106May 10, 202213F-HRchanges · EDGAR ↗
Q4 2021$664M108Feb 11, 202213F-HRchanges · EDGAR ↗
Q3 2021$1.2B127Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$1.2B127Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$1.3B113May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$1.4B97Feb 12, 202113F-HRchanges · EDGAR ↗
Q3 2020$1.2B88Nov 13, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.1B191Aug 13, 202013F-HRchanges · EDGAR ↗
Q1 2020$521M65May 13, 202013F-HRchanges · EDGAR ↗
Q4 2019$670M65Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$580M63Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$836M92Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$831M106May 14, 201913F-HRchanges · EDGAR ↗
Q4 2018$736M104Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.